Overview

* Innoviva Q3 2025 total revenue grows 20% yr/yr, driven by royalties and product sales

* Net income for Q3 2025 soars to $89.9 mln from $1.2 mln last year

* Company announces $125 mln share repurchase program

Outlook

* Company did not provide specific financial guidance for future quarters or fiscal year

Result Drivers

* ROYALTIES GROWTH - Co reports 5% growth in royalties portfolio, highlighting resilience

* IST SALES GROWTH - IST achieved 52% yr/yr growth in U.S. net product sales

* ZEVTERA LAUNCH - Early market receptivity for ZEVTERA following U.S. launch over summer

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $59.9

Royalty mln

Revenue

Q3 Net $89.91

Income mln

Q3 $97.82

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Innoviva Inc ( INVA ) is $35.00, about 48.1% above its November 4 closing price of $18.15

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)